Clinical Trial Update: Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing once-daily sevelamer dosing with three-times-daily dosing in chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Sevelamer (sevelamer hydrochloride)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Chronic Kidney Disease | Phase 2 | Status: COMPLETED